These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18992710)

  • 1. NF-kappaB functions in osteoclasts.
    Soysa NS; Alles N
    Biochem Biophys Res Commun; 2009 Jan; 378(1):1-5. PubMed ID: 18992710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis.
    Soysa NS; Alles N; Weih D; Lovas A; Mian AH; Shimokawa H; Yasuda H; Weih F; Jimi E; Ohya K; Aoki K
    J Bone Miner Res; 2010 Apr; 25(4):809-18. PubMed ID: 19839765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Processing of the NF-kappa B2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation.
    Maruyama T; Fukushima H; Nakao K; Shin M; Yasuda H; Weih F; Doi T; Aoki K; Alles N; Ohya K; Hosokawa R; Jimi E
    J Bone Miner Res; 2010 May; 25(5):1058-67. PubMed ID: 19874202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival.
    Hwang YH; Lee JW; Hahm ER; Jung KC; Lee JH; Park CH; Rhee HS; Ryu JM; Kim HK; Yang CH
    Biochem Biophys Res Commun; 2005 Nov; 337(3):815-23. PubMed ID: 16213465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF-kappaB modulators in osteolytic bone diseases.
    Xu J; Wu HF; Ang ES; Yip K; Woloszyn M; Zheng MH; Tan RX
    Cytokine Growth Factor Rev; 2009 Feb; 20(1):7-17. PubMed ID: 19046922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-kappaB.
    Lin RW; Chen CH; Wang YH; Ho ML; Hung SH; Chen IS; Wang GJ
    Biochem Biophys Res Commun; 2009 Feb; 379(4):1033-7. PubMed ID: 19150340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active caspase-3 is required for osteoclast differentiation.
    Szymczyk KH; Freeman TA; Adams CS; Srinivas V; Steinbeck MJ
    J Cell Physiol; 2006 Dec; 209(3):836-44. PubMed ID: 16972256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical Roles of NF-κB Signaling Molecules in Bone Metabolism Revealed by Genetic Mutations in Osteopetrosis.
    Jimi E; Katagiri T
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LIM-homeodomain transcription factor LMX1B regulates expression of NF-kappa B target genes.
    Rascle A; Neumann T; Raschta AS; Neumann A; Heining E; Kastner J; Witzgall R
    Exp Cell Res; 2009 Jan; 315(1):76-96. PubMed ID: 18996370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
    J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR gamma: ally and foe in bone metabolism.
    Wahli W
    Cell Metab; 2008 Mar; 7(3):188-90. PubMed ID: 18316021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAF6 negatively regulates TNFalpha-induced NF-kappaB activation.
    Funakoshi-Tago M; Kamada N; Shimizu T; Hashiguchi Y; Tago K; Sonoda Y; Kasahara T
    Cytokine; 2009 Feb; 45(2):72-9. PubMed ID: 19091594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NF-kappaB activity prevents downregulation of alpha1-adrenergic receptors and circulatory failure during CLP-induced sepsis.
    Schmidt C; Kurt B; Höcherl K; Bucher M
    Shock; 2009 Sep; 32(3):239-46. PubMed ID: 19106815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirement for NF-kappaB in osteoclast and B-cell development.
    Franzoso G; Carlson L; Xing L; Poljak L; Shores EW; Brown KD; Leonardi A; Tran T; Boyce BF; Siebenlist U
    Genes Dev; 1997 Dec; 11(24):3482-96. PubMed ID: 9407039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction.
    Timmers L; van Keulen JK; Hoefer IE; Meijs MF; van Middelaar B; den Ouden K; van Echteld CJ; Pasterkamp G; de Kleijn DP
    Circ Res; 2009 Mar; 104(5):699-706. PubMed ID: 19168865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the zinc transporter ZIP1 in osteoclasts.
    Khadeer MA; Sahu SN; Bai G; Abdulla S; Gupta A
    Bone; 2005 Sep; 37(3):296-304. PubMed ID: 16005272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.